Navigation Links
Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
Date:10/19/2009

SAN FRANCISCO, Oct. 19 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

European Orphan Drug Designation encourages the development of products that demonstrate promise for the treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union. The designation criteria also specify that there is no other satisfactory therapy for that indication and that if JX-594 is shown to be effective in pivotal trials, it would represent a significant clinical benefit to HCC patients. Orphan Drug status for JX-594 entitles Jennerex to 10 year market exclusivity in Europe if the Market Authorization Application (MAA) is approved as well as potentially increasing reimbursement pricing. The designation also confers special benefits, including eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of application for marketing approval.

"This designation is an important step in the development of a potential breakthrough treatment for this lethal disease," said David H. Kirn, M.D., President and Chief Executive Officer of Jennerex. "We look forward to working closely with the European regulatory authorities to complete the global development of JX-594 for the treatment of primary liver cancer."

About Hepatocellular Carcinoma

The treatment of advanced hepatocellular carcinoma represents a significant unmet medical need. HCC
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Texas , Sept. 4, 2015  Luminex Corporation ... present at the Morgan Stanley Global Healthcare Conference to ... Grand Hyatt Hotel in New York City ... at 11:40 a.m. Eastern time on Friday, September 18, ... accessed at Luminex Corporation,s website at http://www.luminexcorp.com . ...
(Date:9/4/2015)... SOUTH PLAINFIELD, N.J. , Sept. 4, 2015 ... is pleased to announce five recipients of its ... to Realize Innovation, Vision and Empowerment), designed to ... the Duchenne muscular dystrophy (DMD) community. The announcement ... for the international World Duchenne Awareness Day on ...
(Date:9/4/2015)... Future Prospects for Companies in ... Rhinitis drugs - new study showing you trends, ... market for allergic rhinitis drugs heading? What are the ... report shows you potential revenues and other trends to ... 326 page report provides 273 tables, charts, and graphs. ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7
... , EXTON, Pa., Oct. 9 Kensey Nash ... release its earnings results for its first quarter ended September ... 22, 2009. , Joe Kaufmann, President and CEO, ... Thursday, October 22, 2009 at 9:00 A.M. Eastern Time. ...
... 9 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ... announced sale of shares of its Series D convertible ... institutional investors, representing gross proceeds to ADVENTRX of approximately ... from the offering to fund its operations during the ...
Cached Medicine Technology:Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2ADVENTRX Pharmaceuticals Announces Closing of Financing 2ADVENTRX Pharmaceuticals Announces Closing of Financing 3
(Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts ... the Year” awards at this year’s Microsoft Worldwide Partner Conference that was held ... the Year” Award Winner for Data Platform services, the 2015 HP and Microsoft ...
(Date:9/4/2015)... Francisco, CA (PRWEB) , ... September 04, 2015 ... ... Amini, announces that CEREC technology is now available at CitiDent. CEREC is a ... machinery. In addition to saving time for patients by eliminating the need for ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Mike Day, a ... 2007, will compete in the Ironman World Championships in Kona on October 10th. , ... incurred Traumatic Brain Injury (TBI) through combat and the cutting-edge treatments that restore their ...
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a ... announced its only mission and research focus: Water Life Science®. In the current ... water evaporation is becoming dangerously accelerated. As a result of the global fresh ...
(Date:9/4/2015)... ME (PRWEB) , ... September 04, 2015 , ... ... focus on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 at ... , Speakers at the 2015 symposium are doctors and researchers at the top ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... 22-hour procedure replaced 80% of severely disfigured woman,s face, ... A team of eight Cleveland Clinic surgeons has completed ... most of the woman,s face, including about 80 percent ... most of the sinuses, upper jaw -- essentially ...
... Calif., Dec. 17 Human Pheromone,Sciences, Inc. (OTC Bulletin ... filed a Comprehensive Patent Application with the U.S. Patent ... previously undeveloped,compound with its origin in sea coral, which ... feelings of positive social relationships,personal well-being and social attraction. ...
... LLC today announced positive results from a Phase 2 ... Multiple Sclerosis patients with documented cognitive dysfunction. , ... study, Cognition Pharmaceuticals reported, the active group obtained significantly ... learning, including the Brief Visuospatial Memory Test - Revised, ...
... Jude Children,s Research Hospital have answered a central question ... rise to tumors. Stem cells are immature cells that ... cells that compose the range of body tissues. In ... arise from mutant forms of stem cells. , ...
... Dec. 17 Time Life is proud to announce they have teamed ... a brand new fitness program set to dance hits of the ,70s, ... , Cheryl Burke has been dancing since the age ... titles around the world. For the past six television seasons, the ...
... Mass., Dec. 17 Hologic, Inc. (Nasdaq: HOLX ... medical imaging systems and surgical products dedicated to serving the ... first quarter fiscal 2009 operating results on Monday, February 2, ... will host a conference call on Monday, February 2, 2009 ...
Cached Medicine News:Health News:Doctors Describe First U.S. Face Transplant 2Health News:Doctors Describe First U.S. Face Transplant 3Health News:Doctors Describe First U.S. Face Transplant 4Health News:HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral 2Health News:Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis 2Health News:Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis 3Health News:Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis 4Health News:Molecular marker identifies normal stem cells as intestinal tumor source 2Health News:Cheryl Burke of 'Dancing with the Stars' Joins Forces With Time Life To Create a Brand New Dance Workout, 'DISCO ABS' 2Health News:Cheryl Burke of 'Dancing with the Stars' Joins Forces With Time Life To Create a Brand New Dance Workout, 'DISCO ABS' 3Health News:Hologic, Inc. to Release First Quarter Fiscal 2009 Operating Results on Monday, February 2, 2009 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: